Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04313218
Other study ID # OBSGYN 1
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2018
Est. completion date February 28, 2020

Study information

Verified date March 2020
Source Port Said University hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cesarean section is one of the most common surgeries practiced for save delivery of the fetus, however it is not a safe route of delivery its incidence is rising especially in high and middle income countries. The major concern is that the average blood loss during cesarean delivery is 487 ml, this amount is too close to the definition of postpartum hemorrhage by WHO as loss of 500 cc of blood in the first 24 hours after delivery making control of blood loss during cesarean delivery crucial to decrease maternal morbidities.This study aim to compare the use of misoprostol to carbetocin in reducing blood loss during cesarean section in low risk patients


Description:

Cesarean section is one of the most common surgeries practiced for save delivery of the fetus, however it is not a safe route of delivery its incidence is rising especially in high and middle income countries. Although the WHO recommended cesarean section rate between 10 to 15% to decline the maternal mortality ratio and Neonatal mortality ratio, the incidence show sharp increase especially in Egypt to reach 52% of all deliveries. The major concern is that the average blood loss during cesarean delivery is 487 ml, this amount is too close to the definition of postpartum hemorrhage by WHO as loss of 500 cc of blood in the first 24 hours after delivery making control of blood loss during cesarean delivery crucial to decrease maternal morbidities. Many medications used to decrease blood loss especially placental site bleeding during cesarean section including oxytocin, ergometrine, synthetic prostaglandins and recently carbetocin.

Carbetocin is an oxytocin analogue containing eight amino acids .It binds to oxytocin receptors expressed on uterine muscles of pregnant women inducing tetanic uterine contractions for about 11 minutes after administration of 8-30ug intravenous followed by rhythmic uterine contractions that last for 60 to 120 minutes. Also it has a longer half life time than oxytocin and the recommended dose is 100ug IV.

Misoprostol is synthetic analogue to prostaglandin which is cheap heat stable uterotonic making it the alternative of choice to intravenous oxytocin in low resources countries. The recommended dose for prophylaxis against postpartum hemorrhage is 600μg while 800μg is used as a treatment.

In the lack of sufficient studies comparing the use of carbetocin to misoprostol to decrease blood loss during cesarean section we perform this study to compare the use of misoprostol to carbetocin in reducing blood loss during cesarean section.

Patients and Methods This was a retrospective comparative study conducted in Port Said General Hospital And Private practice in Port Said Egypt. Following approval of the study protocol by the ethical committee in Faculty of medicine Port Said University. The medical records of patients in the period from January 2018 to February 2019 were searched; women who underwent CS and were considered at low risk for postpartum including 1- singleton pregnancy, 2- less than previous four deliveries, 3- elective lower segment C.S, 4- C.S was done under general anesthesia 5- No medical disorders complicating pregnancy, 6- Placenta neither previa nor morbidly adherent, 7- Average amount of amniotic fluid, 8- No past history of postpartum hemorrhage and 9- No contraindications to Misopristol or Carbetocin 300 patients were eligible and were enrolled in this study. Women who received Carbetocin 100ug i.v (PABAL 100 micrograms/ml solution for injection, Ferring Pharmaceuticals Ltd) intra operative immediately after extraction of the fetus, were enrolled into group A and women who received misoprostol 600ug (cytotec 200ug tablet, Pfizer G.D. Searle LLC) rectally immediately before sterilization during caesarean section were enrolled into group B.

Maternal data (demographic and clinical), ultrasound findings, operative details, and postoperative characteristics were recorded in a database. The outcome measures of this study were the need for blood products transfusion, the amount of blood products transfusion, the operative time, operative complications uterine atony the need for surgical interventions to stop bleeding as uterine artery ligation and uterine compression sutures and the deficit in hemoglobin level.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date February 28, 2020
Est. primary completion date February 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- parity less than 4

- unscarred uterus or previous one cesarean section

- elective C.S

- general anesthesia

Exclusion Criteria:

- medical disorders complicating pregnancy

- more than one C.S

- selective C.S

- Risk factors for Postpartum hemorrhage

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Carbetocin
iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section

Locations

Country Name City State
Egypt Waleed Elsayed Elrefaie Port Said NY

Sponsors (1)

Lead Sponsor Collaborator
Port Said University hospital

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary blood loss reduction of blood loss during cesarean section operation during operation
See also
  Status Clinical Trial Phase
Terminated NCT04377984 - Impact of a Strategy Combining Morphine Savings and Anesthesia Technique on the Quality of Post-operative Rehabilitation
Recruiting NCT03248817 - Phenylephrine Infusion in Cesarean Delivery Phase 4
Completed NCT05037383 - Motion and Viewing Analysis of Surgeons During Minimally Invasive Gynecological Interventions N/A
Completed NCT05933993 - Mothers Experience of Pain Following Elective Cesarean Section. A Qualitative Study.
Recruiting NCT05021315 - Vaginal Cleaning Using Povidone Iodine Before CS to Reduce Postoperative Wound Infection Phase 3
Terminated NCT03246919 - Ideal Time of Oxytocin Infusion During Cesarean Section Phase 4
Completed NCT06403215 - Effect of Chewing Gum and Drinking Fennel Tea N/A
Not yet recruiting NCT06446258 - Assessment of the Impact of Soft Tissue Mobilization on the Scar in Patients After Cesarean Section N/A
Recruiting NCT06247852 - Persistent Pain After Cesarean Delivery - A Danish Multicenter Cohort Study
Not yet recruiting NCT06017076 - Effect of Preoperative Oral Energy Drinks Compared to Warming Matress on Body Temperature During Combined Spinal-epidural Anesthesia for Elective Cesarean Delivery. N/A
Completed NCT05005871 - Comparison of Quadratus Lumborum Intramuscular and Transmuscular in Postoperative Pain N/A
Recruiting NCT04518176 - Bilateral Uterine Artery Ligation During the Cesarean Delivery of Twins N/A
Not yet recruiting NCT04505644 - Lidocaine Patch Versus Intravenous Lidocaine in Pain Relief After Cesarean Section N/A
Not yet recruiting NCT03985618 - The MODE Trial: Planned Caesarean Section Versus Induction of Labour for Women With Class III Obesity N/A
Completed NCT04046510 - Comparaison of 3 Protocols of Ocytocin Administration in C Section N/A
Completed NCT03302039 - Three Protocols for Phenylephrine Administration in Cesarean Delivery Phase 4
Completed NCT03318536 - Effect of Granisetron on Usage of Sympathomimetics During Caesarean Section
Recruiting NCT03682510 - B-Lynch Transverse Compression Suture Versus a Sandwich Technique (N&H Technique) for Complete Placenta Previa N/A
Recruiting NCT03651076 - Traxi Panniculus Retractor for Cesarean Delivery N/A
Not yet recruiting NCT06060327 - Comparing Tranexamic Acid Versus Ecbolics in Preventing Hemorrhage During and After Cesarean Section N/A